

Global CF Integration Grant Submission Form

Please complete the application form and upload two pdf documents

Case for Support (maximum 10 pages) this must include:

1. Rationale and aims
2. Hypothesis and research question
3. Methods, study design, techniques, data analysis
4. Anticipated difficulties & alternative approaches
5. Expected deliverables and impact on people with CF
6. Management and governance plan for the integrated collaboration
7. Timeline
8. Unpublished data to support the hypothesis and or feasibility (2 pages maximum)
9. References (2 pages maximum)

And

CVs - maximum 2 pages per investigator using the template provided in the Grant Guidelines

HOW FUNDS WILL BE AWARDED

The Australian funds for this grant will be awarded from Cure4CF and the UK funds will be awarded from the Cystic Fibrosis Trust.

Where the Lead PI is based in Australia, an award letter will be issued to the UK partner, allowing them to invoice the Cystic Fibrosis Trust directly for their costs. Similarly, where the Lead PI is based in the UK, an award letter will be issued to the Australian partner, allowing them to invoice Cure4CF directly for their costs.

The award letters will also outline specific reporting requirements for each country.

PROJECT OVERVIEW

Project Title

Administering Institution Name

Administering Institution Address

Finance Officer responsible for administering this grant

Proposed Start Date

Project duration (months)

PRINCIPAL INVESTIGATOR DETAILS

Surname

Forenames

Title and position name

Email

Contact address

Daytime phone number

Mobile phone number

Proportion of time working on this project (%)

Residency status

- ☐ Australian citizen
☐ Australian resident
☐ UK resident

CO-INVESTIGATOR DETAILS

Co-investigator 1

Name, position and title

Co-investigator 1

Email

Co-investigator 1

Contact address

Co-investigator 1

Daytime phone number

Co-investigator 1

Mobile phone number

Would you like to add another co-investigator

☐ Yes
☐ No

Co-investigator 2

Name, position and title

Co-investigator 2

Email

Co-investigator 2

Contact address

Co-investigator 2

Daytime phone number

Co-investigator 2

Mobile phone number

Would you like to add another co-investigator

☐ Yes
☐ No

Co-investigator 3

Name, position and title

Co-investigator 3

Email

Co-investigator 3

Contact address

Co-investigator 3

Daytime phone number

Co-investigator 3

Mobile phone number

Would you like to add another co-investigator

☐ Yes
☐ No

Co-investigator 4

Name, position and title

Co-investigator 4

Email

Co-investigator 4

Contact address

Co-investigator 4

Daytime phone number

Co-investigator 4

Mobile phone number

Would you like to add another co-investigator

☐ Yes
☐ No

Additional co-investigators

Please add the name, email and mobile phone number of
any additional investigators

COLLABORATION

Please provide a statement to support your previous collaboration with the proposed investigator team

Have you or any of your co-investigators applied, or do you plan to apply, for funding for this or a related project from another organisation?

- ☐ Yes
☐ No

Provide details of other applications

Does this project involve collaboration with other groups not named as applicants?

- ☐ Yes
☐ No

Please specify the other collaborators including names and institutions

Upload a letter of support from collaborators that are not investigators

RESEARCH PRIORITY ALIGNMENT**Research priority statements**

Cystic Fibrosis Trust: 'Ground-breaking research that is of imminent and/or important relevance to people with cystic fibrosis'

Cure4CF: 'Innovative and high- impact research that includes a clear pathway to deliver tangible and beneficial outcomes for our community'

How does this research proposal align with the Cure4CF and CF Trust research priorities?

PLAIN LANGUAGE SUMMARY

This will be used to review your application by community members of the Review Committee and may be published on our websites if the grant is successful. This must be targeted at a community audience, emphasising the importance of the work to people with cystic fibrosis and how this work addresses an unmet clinical need.

Please outline:

The problem you will address and why it matters to the CF community

What is known already about this problem and what evidence is there to support the importance of the identified problem

Which of the refreshed JLA priorities you will be addressing (see link below)

What your project will do and how it will add to the current evidence

What is the expected short- and long-term impact of this work on the CF community

<https://www.cysticfibrosis.org.uk/research/your-cf-research-priorities>

Plain Language Summary of the proposed research

Please include key goals

CONSUMER/PATIENT AND COMMUNITY/PUBLIC INVOLVEMENT

Describe how consumers/patients have contributed to the development of this research plan, and how you will continue to engage them throughout the project

CLINICAL RELEVANCE, TRANSLATION AND SUSTAINABILITY

Outline the clinical relevance and intended impact of this research proposal to people with cystic fibrosis including what the intended product or service that will be ultimately delivered

Include any sub-patient populations that may be involved.

Following the completion of this research project, what are the next steps in the translation process and how do you plan to support this?

Consider plan for attracting further funding, please include which funding body and initiative you intend to apply for and what kind of work is required to be undertaken e.g. further pre-clinical work, clinical trials, regulatory steps, implementation activities

INTELLECTUAL PROPERTY

Is the proposed research likely to lead to patentable or commercially exploitable results?

☐ Yes
☐ No

Briefly describe any expected patentable or commercially valuable outcomes, and how you plan to manage them

Does the proposed research require access to any third-party intellectual property?

☐ Yes
☐ No

Outline how appropriate rights have been or will be secured to allow the development of this project

How does the intellectual property position and plan for this research support a clear and timely pathway to clinical impact?

HUMAN ETHICS

Will human participants or samples be used?

- ☐ Yes
☐ No

How many patients or human samples will be involved in total?

Does the research involve primary data collection from participants?

- ☐ Yes
☐ No

What is the recruitment strategy and any strategy related to the target sex and/or gender distribution?

Does the research involve the use of secondary data?

- ☐ Yes
☐ No

Provide a description of the sex and/or gender distribution of participants in the original dataset

Is the research pre-clinical

- ☐ Yes
☐ No

What are your planned actions for procuring, managing and storing the samples and how you have chosen your target sex distribution of samples?

For pre-clinical research involving the use of secondary data, please provide a description of the sex distribution of subjects in the original dataset

What consideration have been given to equity, diversity and inclusion in identifying and involving patients / human subjects?

Will the study account for sex or gender or both to answer the research question?

- ☐ Yes
☐ No
☐ NA

Which sex and/or gender characteristic(s) will be considered and accounted for, and which research participants/subjects will be included to reflect these characteristic(s)

Name of human ethics committee

Has human ethics been approved?

- ☐ Yes
☐ No

Human ethics approval date

Is human ethics approval pending?

- ☐ Yes
☐ No

Date of expected approval

Is human ethics yet to be submitted

☐ Yes
☐ No

Anticipated date of submission

Please outline your timeline for ethics submission
including contingencies for delays

Please outline why human ethics is not needed

ANIMAL ETHICS

Will animals be used?

☐ Yes
☐ No

Has full consideration been given to the use of alternatives?

☐ Yes
☐ No

Have the experiments been approved by your institution's Animal Ethics Committee?

☐ Yes
☐ No

Please provide the approval number, date and committee name

Please explain why animal ethics has not been approved

State the species to be used, (including those not protected under UK law) the number of each and whether any genetically modified animals will be used.

Please note:

Applications involving non-human primates will not be considered for this funding round.

Applications involving cats, dogs, or equines, will be referred to the NC3Rs (enquiries@nc3rs.org.uk) for additional expert 3Rs review.

State the sex of the species used

If not able to or if only using same sex species, please include the rationale for why

What is the target distribution of animal by sex and/or gender

Please provide the rationale for why this distribution has been selected to answer the research question

Please provide details of any planned sex disaggregated analysis

If you are not planning to perform a sex- and/or gender-disaggregated analysis, please explain why

Does the research include procedures to be carried out on animals in the UK under the Animals (Scientific Procedures) Act 1986?

☐ Yes
☐ No

Please give the details of the Home Office and Ethical Review Body (AWERB) license number (personal) for each researcher involved in animal experiments.

Please also attach copies of any licences and approvals that have been granted to your application form. Please note all successful projects will be required to send copies of approval once they have been granted

Will the proposals involve the use of animals outside the UK or animal tissue sourced from outside the UK?

☐ Yes
☐ No

Please provide details on assurance that the research will be conducted according to the spirit of UK legislation and to required UK welfare standards

see page 14 of the Responsibility document:
Responsibility in the use of animals in bioscience research | NC3Rs

EQUITY, DIVERSITY AND INCLUSION

Describe how your research design addresses diversity and promotes inclusion.

Consider the population groups who may benefit from this research, including any underserved communities.

Where relevant, include how your approach is supported by workplace policies or practices.

USE OF AI TOOLS

Have any generative AI tools been used when completing this application?

☐ Yes
☐ No

Clearly attribute outputs from generative AI tools used in this application

List the generative AI source and where possible name the specific model/s and software used and specify how the content was generated (such as listing the prompt used)

Do you plan to use AI when conducting the research project?

☐ Yes
☐ No

How will the AI tool be used in the research project

Include the characteristics of the tool, has it been validated and if so how, is it adaptive or non-adaptive, and what limits apply to permitted adaptations

Will participant data be entered into any AI system operated by a third party?

☐ Yes
☐ No

Describe your plan for the oversight of the AI and the outputs

Consider safeguards, bias, team skills, performance monitoring, team AI training

Describe the risks associated with your use of the AI tool in your research and your plan to mitigate and manage those risks

AUSTRALIAN BUDGET

Person 1: Salary description

Please provide:

Name if known

Salary grade

Supervising investigator name

Proportion of time on project (%)

Person 1: Total salary requested (AUD)

Person 2: Salary description

Please provide:

Name if known,

Salary grade

Supervising investigator name

Proportion of time on project (%)

Person 2: Total salary requested (AUD)

If you require more than 2 salaries funded in AUD
please outline these here

Other salary cost (AUD)

(please provide the cost of the salaries for any
additional team members not provided as Person 1 or
Person 2)

Materials and consumables

Please outline the materials and consumables requested

Total cost of materials and consumables (AUD)

Other research costs

Please describe other costs here including travel,
consumer or patient engagement etc.

Total Cost of other research costs (AUD)

Total costs of animals if required (AUD)

Include purchase, maintenance and procedures

UK BUDGET

Person 1: Salary description

Please provide:

Name if known,

Salary grade

Supervising investigator name

Proportion of time on project (%)

Person 1: Salary requested (GBP)

Person 2: Salary description

Please provide:

Name if known,

Salary grade

supervising investigator name

Proportion of time on project

Person 2: Salary requested (GBP)

If you require more than 2 salaries funded in GBP
please outline these here

Other salary cost (GBP)

(please provide the cost of the salaries for any
additional team members not provided as Person 1 or
Person 2)

Materials and consumables

Please outline the materials and consumables requested

Total cost of materials and consumables (GBP)

Other research costs description

Please describe other costs here including travel,
consumer or patient engagement etc.

Total cost of other research costs (GBP)

Total costs of animals if required (GBP).

Include purchase, maintenance and procedures

Total Funding Requested AUD

Total Funding Requested GBP

CASE FOR SUPPORT AND CV UPLOAD

Case for support

Investigators CV

DECLARATION

1. To the best of my knowledge, the information provided in this application is accurate and complete.
2. I have read the conditions under which grants are awarded and, if a grant is made, I/we agree to abide by them.
3. I agree to advise Cure4CF Foundation and Cystic Fibrosis Trust immediately of any change to the status of the researchers within the host institution, or of any scientific, managerial or administrative issue that might affect the direction or completion of the research as originally planned.
4. The necessary facilities will be made available to conduct this research and will be available for the duration of the award.
5. I acknowledge that Cure4CF Foundation and Cystic Fibrosis Trust cannot act as Sponsor of any research funded by this award and agree that the Institution will fulfil the responsibilities of the Sponsor if a grant is made.
6. I understand that by submitting this application that the application, and all the information contained within, will be sent to a selection of peer reviewers identified for review purposes.